Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients

May 26, 2011 By Bio-Medicine.Org

BONITA SPRINGS, Fla., May 26, 2011 /PRNewswire/ — Tigris
Pharmaceuticals, Inc., today announced enrollment of its first
patient in a randomized Phase 2 clinical trial of AFP-464
(aminoflavone prodrug) with or without Faslodex® (fulvestrant)
in estrogen receptor (ER)-positive breast cancer patients.
Molecular profiling will be used to pre-screen patients for a
biomarker called Aryl Hydrocarbon Receptor (AhR), which has shown
to predict sensitivity to AFP-464.

It is estimated that approximately 70 percent of breast cancers
are ER-positive (1).

“The promise of personalized medicine is being realized with
this study of AFP-464,” said Edmundo Muniz, M.D., Ph.D., president
and chief executive officer of Tigris Pharmaceuticals. “Matching
specific markers and gene variations to particular medicines is a
more efficient way of developing new anti-cancer agents and more
importantly, will enable doctors to make more informed prescribing
decisions, reducing risks of side effects and increasing chances of
treatment success.”

The primary endpoint of the study is to determine the percentage
of patients that achieve a Clinical Benefit Response.

The randomized, proof-of-concept trial is led by Joanne Blum,
M.D., Ph.D., director of the Hereditary Cancer Risk Program at
Baylor-Sammons Cancer Center in Dallas, Texas. The study is open
for accrual with the US Oncology Research Network, the largest
community-based cancer research network in the nation.

“We are fortunate there are approved therapies to treat
metastatic breast cancer, but the majority of patients with this
disease will become refractory during  treatment,” said Dr.
Blum. “This study is exciting in that it may have the potential to
improve our ability to deliver targeted cancer therapy at the
outset of treatment providing another option for these
patients.  Additionally, this agent may help to overcome
endocrine resistance, one of the major problems for patients

‘/>”/>

SOURCE

Related Articles Read More >

Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech